Michael Weiner, MD, Sharon Cohen, MD, FRCPC, Oskar Hansson, MD, PhD

Are you up to date on how the field of Alzheimer's disease diagnosis is changing? Learn from Michael Weiner, MD, Sharon Cohen, MD, FRCPC, and Oskar Hansson, MD, PhD about current and emerging biomarkers of Alzheimer's disease, and improve your ability to describe biomarkers measured in Alzheimer's disease (AD), the relationship between AD biomarkers and clinical disease expression, and how biomarkers are used in clinical practice in the care of patients with AD.

Charlotte Teunissen, Professor of Neurochemistry at the Vrije Universiteit Amsterdam, Netherlands

Professor Charlotte Teunissen describes the benefits and limitations of using diagnostic biomarkers in Alzheimer’s disease, and reviews the latest innovations concerning neuroimaging, CSF and blood-based biomarkers
- Focus on neuroimaging and CSF biomarkers to help confirm an Alzheimer’s diagnosis
- Learn validation evidence for new blood-based biomarkers that meets some unmet needs

Douglas R. Galasko, MD; Leslie M. Shaw, PhD; Henrik Zetterberg, MD, PhD

During this panel discussion with Leslie M. Shaw, PhD and Henrik Zetterberg, MD, PhD, moderated by Douglas R. Galasko, MD, you will learn how to better identify clinically relevant biomarkers in AD, differences between available biomarkers, and how to interpret the results of biomarker testing. CMEs are available as part of this education.

This set of five interactive learning modules will explore various concepts on the clinical application of CSF and blood-based biomarkers in the timely diagnosis of Alzheimer's disease. Such titles include:
- Understanding the clinical value of CSF biomarkers
- Using standardised CSF testing to support a timely diagnosis
- Optimising the diagnostic pathway with fluid biomarkers
- Examining the significance of robustness for the clinical use of blood-based biomarkers
- Recognising the clinical value of CSF biomarkers through real-world case studies